Janus Henderson Group PLC Has $12.96 Million Position in Equillium, Inc. $EQ

Janus Henderson Group PLC raised its stake in shares of Equillium, Inc. (NASDAQ:EQ) by 10.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,494,571 shares of the company’s stock after purchasing an additional 632,359 shares during the period. Janus Henderson Group PLC owned 0.10% of Equillium worth $12,957,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of EQ. Virtu Financial LLC grew its stake in Equillium by 133.4% in the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after buying an additional 13,591 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Equillium in the first quarter worth about $31,000. State Street Corp lifted its position in shares of Equillium by 13.0% during the 4th quarter. State Street Corp now owns 155,420 shares of the company’s stock worth $241,000 after purchasing an additional 17,900 shares during the last quarter. Persistent Asset Partners Ltd boosted its stake in Equillium by 35.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock valued at $144,000 after purchasing an additional 24,132 shares during the period. Finally, Millennium Management LLC acquired a new stake in Equillium in the 3rd quarter valued at approximately $35,000. 27.05% of the stock is currently owned by institutional investors and hedge funds.

Equillium Stock Up 2.7%

NASDAQ EQ opened at $2.26 on Wednesday. Equillium, Inc. has a twelve month low of $0.46 and a twelve month high of $3.54. The stock has a market cap of $142.90 million, a P/E ratio of -7.06 and a beta of 1.82. The company’s 50-day simple moving average is $2.77 and its 200 day simple moving average is $2.18.

Equillium (NASDAQ:EQ) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Research analysts anticipate that Equillium, Inc. will post -0.24 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on EQ shares. B. Riley Financial began coverage on Equillium in a report on Thursday, April 16th. They set a “buy” rating and a $6.00 price target for the company. Stifel Nicolaus set a $5.00 price objective on shares of Equillium in a research report on Thursday, May 28th. Wall Street Zen lowered Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Roth Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Equillium in a research report on Thursday, May 28th. Finally, Oppenheimer initiated coverage on Equillium in a research report on Thursday, April 23rd. They set an “outperform” rating and a $7.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

Insider Activity at Equillium

In other Equillium news, insider Stephen Connelly sold 30,975 shares of Equillium stock in a transaction on Friday, June 5th. The stock was sold at an average price of $2.94, for a total transaction of $91,066.50. Following the completion of the transaction, the insider directly owned 762,025 shares of the company’s stock, valued at approximately $2,240,353.50. This trade represents a 3.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Penny Tom sold 65,000 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $2.95, for a total transaction of $191,750.00. Following the completion of the sale, the insider owned 65,000 shares in the company, valued at $191,750. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 406,392 shares of company stock valued at $1,224,898 in the last 90 days. 17.84% of the stock is owned by corporate insiders.

Equillium Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.